

March 4, 2024

Ono Announces Status and Completion of Acquisition of Own Shares

(Acquisition of own shares under the Articles of Incorporation pursuant to the provision of Paragraph 2, Article 165 of the Companies Act)

Osaka, Japan, March 4, 2024 - Ono Pharmaceutical Co., Ltd. (President and CEO, Gyo Sagara; “the Company”) today announced that it has acquired its own shares pursuant to the provision of Article 156 of the Companies Act, applied by replacing terms pursuant to the provision of Paragraph 3, Article 165 of the same Act, and that it has completed the acquisition of its own shares in accordance with the resolution passed on July 25, 2023, pursuant to the provisions of Article 370 of the Companies Act (resolution by documents instead of resolution by board meetings).

Particulars

1. Class of shares acquired:	Common stock of the Company
2. Total number of shares acquired:	68,000 shares
3. Total amount of acquisition cost:	169,625,650 yen
4. Period of acquisition:	March 1, 2024 (execution base)
5. Method for acquisition:	Purchased on the Tokyo Stock Exchange

(Reference)

- Details of the resolution by documents instead of resolution at the meeting of Board of Directors on July 25, 2023
 - Class of shares to be acquired: Common stock of the Company
 - Total number of shares to be acquired: 19 million shares (maximum)
(3.89% of the total outstanding shares excluding own shares)
 - Total amount of acquisition cost: 50.0 billion yen (maximum)
 - Period of acquisition: August 1, 2023 to March 22, 2024
- Accumulated Company’s own shares acquired, pursuant to the resolution by documents instead of resolution at the meeting of Board of Directors as of March 1, 2024
 - Total number of shares acquired: 18,732,400 shares
 - Total amount of acquisition cost: 49,999,752,000 yen

Contact:

Ono Pharmaceutical Co., Ltd.

Corporate Communications

public_relations@ono-pharma.com